Therapeutic areas for approved biopharmaceutical NDA in China 2021
In 2021, the Chinese Center for Drug Evaluation of the National Medical Products Administration (NMPA) approved 149 New Drug Applications (NDA) for biopharmaceuticals. 40 percent of all approvals were granted to antineoplastic drugs, while biopharmaceuticals for the treatment of blood system and endocrine system diseases were also prevalent among the approvals.